X

Week in Review: The Latest from PhRMA

Tina Stow   |     October 2, 2015   |   SHARE THIS

week-in-review340B Spotlight:  The latest 340B Spotlight explores contract pharmacy arrangements. Learn more about the history of contract pharmacy arrangements and why a policy change in 2010 led to a dramatic increase in the volume of contract pharmacies.

ICYMI: Dr. Murray Stewart, Chief Medical Officer of GSK, explains why clinical data transparency is the right thing to do and how it can benefit patients. Check it out here

Helping Patients in Time of Need:   Following Hurricane Katrina, the biopharmaceutical industry and the non-profit sector launched Rx Response – a program designed to streamline communication and tackle medicine delivery problems without delay. Now, following its 10 year anniversary, Rx Response has transitioned its name to Healthcare Ready. The new name reflects an expanded effort to work with stakeholders in communities, the government and the private sector to strengthen the entire health care system. Learn more here.

Celebrating Cardiovascular Health: Tuesday, September 29, marked World Heart Day – an opportunity to acknowledge advances in cardiovascular science and disease prevention.  Learn more about how America’s biopharmaceutical companies are working to develop new treatments and cures for the more than 83 million Americans living with heart disease.

Medicare Monday: This week’s post examines how Medicare Part B pays for medicines.

Tina Stow

Tina Stow Tina Stow previously served as Vice President of Communications at PhRMA. Prior to joining PhRMA in 2014, she spent more than a dozen years in corporate and agency communications and public affairs roles. A D.C. transplant via North Carolina and Georgia, Tina likes to travel, make the rounds to D.C.’s new restaurants, dote on her rescue labradoodle (Chloe), and complain about winter.

Topics: Clinical Trials, 340B, Medicare, heart disease

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates